Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

In this deep dive, BioSpace explores the diverse therapeutic modalities now in development, as well as the opportunities and ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo in stomach and esophageal cancers based on PD-L1 expression levels—but the ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...